Feb. 8, 2026 •
Somewhat-Bullish
Federated Hermes Inc. significantly reduced its stake in Keysight Technologies Inc. (NYSE:KEYS) by 67% in Q3, selling 7,581 shares and retaining 3,726 shares valued at $652,000. Despite this sell-off, Keysight Technologies has a "Moderate Buy" consensus rating from analysts with an average target price of $221.64, and the company recently authorized a $1.50 billion share buyback program. Insiders have also been selling shares, while institutional ownership stands at 84.58%.
Feb. 7, 2026 •
Somewhat-Bullish
Thermo Fisher Scientific (TMO) has experienced recent share price weakness despite long-term positive returns and strong profitability. The article analyzes TMO's valuation, finding it slightly overvalued based on a narrative fair value model ($540.27 vs. $542.83 current price), while its P/E ratio suggests less froth compared to industry peers. Investors are encouraged to consider the company's growth, balance sheet, and cash generation profile, along with potential risks, when assessing investment opportunities.
Feb. 7, 2026 •
Neutral
This article provides comprehensive stock information for Agilent Technologies Inc (A), including its current stock price, key financial metrics, analyst ratings, and recent news. It details performance indicators, valuation ratios, dividend information, and insider trading activities, offering a snapshot of the company's financial health and market sentiment.
Feb. 7, 2026 •
Somewhat-Bearish
Agilent Technologies Inc.'s short interest has increased by 15.79% since its last report, with 3.85 million shares sold short, representing 1.54% of its float. This rise indicates a more bearish sentiment among investors, although the company's short interest is still lower than its peer group average of 7.35%. Traders would need 2.0 days to cover their short positions, suggesting that while short interest is growing, it remains relatively low compared to industry peers.
Feb. 6, 2026 •
Somewhat-Bullish
Revvity (RVTY) recently introduced new lab automation tools at the SLAS2026 conference, influencing its stock valuation. Despite a recent share price increase, the stock and its P/E ratio are being evaluated against the North American Life Sciences industry average. Analysts suggest Revvity is currently undervalued, with a fair value estimate of US$114.63, driven by expected margin expansion and a shift towards higher-margin offerings.
Feb. 6, 2026 •
Neutral
Agilent Technologies, Inc. has filed a DEFA14A form with the SEC to provide notice for its 2026 Annual Meeting of Stockholders. The meeting will be held on March 18, 2026, where shareholders will vote on the election of four directors, advisory approval of executive compensation, ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and an amendment to declassify the Board of Directors. Proxy materials are available online, and electronic votes must be cast by March 17, 2026.
Feb. 6, 2026 •
Somewhat-Bullish
Linscomb Wealth Inc. has invested $2.94 million in Agilent Technologies (NYSE:A) by purchasing 22,927 shares in the third quarter, aligning with several other institutional investors increasing their stakes. Analysts maintain a "Moderate Buy" rating with a consensus price target of $164.50. Agilent recently reported a slight earnings beat, provided positive guidance for fiscal year 2026, and increased its quarterly dividend.
Feb. 6, 2026 •
Somewhat-Bullish
Agilent Technologies (A) is showcasing new automation and AI lab tools at the SLAS2026 conference, despite a recent decline in its stock price. While a "most popular narrative" suggests the company is 23.6% undervalued with a fair value of $169.67 per share, a Discounted Cash Flow (DCF) model indicates the current share price of $129.64 might be overvalued, suggesting a fair value of $115.94. The article encourages investors to analyze both perspectives to determine Agilent's true valuation.
Feb. 5, 2026 •
Somewhat-Bullish
Penserra Capital Management LLC increased its stake in Keysight Technologies Inc. by 8.8% in Q3 2025, now owning 68,842 shares valued at $12.04 million. Other institutions like Vanguard Group and State Street Corp also increased their holdings. Analysts maintain a "Moderate Buy" rating with an average target price of $221.64, and the company recently authorized a $1.5 billion share buyback after beating Q4 earnings expectations.
Feb. 5, 2026 •
Bullish
Agilent Technologies announced its participation in the SLAS2026 International Conference & Exhibition, where it will showcase its latest automated workflow innovations. The company plans to demonstrate how its integrated automation ecosystem, featuring advanced imaging, software, robotics, and AI, helps accelerate scientific discovery by enhancing efficiency and data quality. Agilent will also preview a new Cytation imaging platform, debut the ProteoAnalyzer Software Security Module for regulatory compliance, and feature AI-driven lab optimization tools within its CrossLab Connect platform.
Feb. 5, 2026 •
Neutral
Agilent Technologies will showcase its next-generation automated workflow innovations at the SLAS2026 International Conference & Exhibition. The company will demonstrate its expanding automation ecosystem, which integrates advanced imaging, software, robotics, and AI-powered optimization, designed to accelerate scientific discovery with efficiency and data quality. Key highlights include a preview of a new Cytation imaging platform, the ProteoAnalyzer Software Security Module for regulatory compliance, and new AI-driven lab optimization tools within its CrossLab Connect platform.
Feb. 4, 2026 •
Somewhat-Bullish
Agilent Technologies Inc. (NYSE: A) announced it will present its next-generation automated workflow innovations at the SLAS2026 International Conference & Exhibition in Boston from February 7-11. The company will showcase its expanded automation ecosystem, which integrates advanced imaging, software, robotics, and AI-powered optimization to enhance laboratory discovery, efficiency, and data quality. Agilent's shares began Wednesday's session up 32 cents at $132.49.
Feb. 4, 2026 •
Somewhat-Bullish
Royal Bank Of Canada raised its price target for Amgen (NASDAQ:AMGN) from $335 to $360, maintaining an "outperform" rating, indicating a potential upside of 4.15%. This upgrade follows Amgen's strong Q4 earnings, where it surpassed analyst expectations for both EPS and revenue. While analyst sentiment is generally positive, there are mixed views, with some cautioning about regulatory challenges and loss of exclusivity impacts on legacy products.
Feb. 4, 2026 •
Somewhat-Bullish
Agilent Technologies Inc. (NYSE: A) announced it will showcase its next-generation automated workflow innovations at the SLAS2026 International Conference & Exhibition in Boston from February 7-11. The company plans to demonstrate how its evolving automation ecosystem, which integrates imaging, software, robotics, and AI-powered optimization, helps laboratories accelerate discovery and improve data quality. Agilent shares started Wednesday's session up 32 cents at $132.49.
Feb. 4, 2026 •
Bullish
Agilent Technologies Inc. announced its participation in the SLAS2026 International Conference & Exhibition, where it will showcase its latest automated workflow innovations. The company will demonstrate its expanding automation ecosystem, including advanced imaging, software, robotics, and AI-powered optimization, designed to accelerate scientific discovery with enhanced efficiency and data quality. Agilent will also debut new platforms like an upcoming addition to the Cytation imaging family and the ProteoAnalyzer Software Security Module, alongside AI-driven lab optimization tools.
Feb. 4, 2026 •
Neutral
Allianz Asset Management GmbH significantly reduced its stake in Agilent Technologies, Inc. by 20.3% in Q3, selling 192,440 shares but still holding 753,449 shares valued at $96.7 million. Despite this, other major institutions like Norges Bank, AQR Capital Management, Ameriprise Financial, and Massachusetts Financial Services Co. substantially increased their holdings in Agilent. Analysts maintain a "Moderate Buy" consensus rating for Agilent, with an average price target of $164.50, following positive quarterly earnings and strong FY2026 guidance.
Feb. 3, 2026 •
Neutral
Agilent Technologies Inc. (NYSE: A) will release its first-quarter fiscal year 2026 financial results after the stock market closes on Wednesday, February 25. The company will host a conference call on the same day at 1:30 p.m. PST to discuss these results. Interested parties can join the listen-only webcast via Agilent’s Investor Relations website, where a recording will also be available for 90 days.
Feb. 3, 2026 •
Neutral
Mediolanum International Funds Ltd reduced its stake in Agilent Technologies by 34.1%, selling 15,620 shares and leaving them with 30,206 shares valued at $3.74 million. This transaction comes amidst ongoing insider selling by company executives and positive analyst sentiment with an average "Moderate Buy" rating and a target price of $164.50. Other institutional investors, like Norges Bank, AQR Capital Management, and Ameriprise Financial, have recently increased their positions in Agilent Technologies.
Feb. 3, 2026 •
Neutral
Delta Air Lines (DAL) is expanding its global network with strategic fleet investments, including the purchase of 31 additional widebody aircraft from Airbus and 30 Boeing 787-10 Dreamliners. While analysts have provided mixed price targets, maintaining "Buy" ratings, the airline continues to strengthen its operations and global reach. Despite its potential, Insider Monkey suggests exploring AI stocks for potentially higher returns with limited downside risk.
Feb. 3, 2026 •
Neutral
Agilent Technologies Inc. (NYSE: A) will release its first-quarter fiscal year 2026 financial results after the stock market closes on February 25, 2026. The company will host a conference call on the same day at 1:30 p.m. PST to discuss these results. Interested parties can access the webcast and a recording on Agilent’s Investor Relations website.